Results 131 to 140 of about 144,000 (291)

The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Inflammation and immune dysfunction may worsen the prognosis of patients with ST‐segment elevation myocardial infarction (STEMI). Aims This study aimed to assess whether the high‐sensitivity C‐reactive protein–albumin–lymphocyte index (hsCALLYI) could be used to predict the prognosis of STEMI patients who received emergency ...
Xinuo Ma, Wei Zhang, Ningli Zhang, Qinghua Zhong, Tao Shi, Sirui Yang, Fazhi Yang, Yujuan Peng, Lixing Chen   +8 more
wiley   +1 more source

Cardiovascular Risk Assessment and Its Determinants Among Older Adults in India: Evidence From a Nationally Representative Survey

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Background Cardiovascular disease (CVD) is the leading cause of mortality, posing a major challenge to its rapidly aging demographic. Early identification of individuals at high risk for future cardiovascular events is paramount for implementing timely preventative strategies.
Vansh Maheshwari, Shyamashree Das, Saurav Basu   +2 more
wiley   +1 more source

Afebrile vancomycin-induced delayed hypersensitivity suggestive of incomplete drug rash with eosinophilia and systemic symptoms syndrome: a case report

Journal of Medical Case Reports
Background Vancomycin-induced delayed hypersensitivity reactions are rare and typically accompanied by systemic symptoms such as fever, eosinophilia, and organ dysfunction, known as drug reaction with eosinophilia and systemic symptoms syndrome. However,
Chien-Hung Chou, Kun-Chuan Chang, Chi-Lan Kao, Kun-Jing Hong   +3 more
doaj   +1 more source

Erratum to “An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity”

Journal of Immunology Research, 2019
Chun-Bing Chen, Riichiro Abe, Ren-You Pan, Chuang-Wei Wang, Shuen-Iu Hung, Yi-Giien Tsai, Wen-Hung Chung   +6 more
doaj   +1 more source

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

Cancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna, Medina Esenbekova, Micheal Bishara, Layo Akinrinwoye, Leila Metellus, Joane Titus   +5 more
wiley   +1 more source

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart, Susan M. Abdel‐Rahman, Gelareh Abulwerdi, Sherbet Samuels, Rebecca Racz, Mohamed A. Mohamoud, Nicholas P. Tatonetti   +6 more
wiley   +1 more source

The β integrin modulates serotonin sensitivity via NPxY motifs to regulate egg laying and mechanosensation behaviors in Caenorhabditis elegans

Developmental Dynamics, EarlyView.
Abstract Background Integrin is an αβ heterodimeric receptor to the extracellular matrix; its binding to the matrix recruits focal adhesions to two NPxY motifs, the tyrosine phosphorylation sites in the cytoplasmic domain. Studies found that replacing tyrosines (Y) with phenylalanines (F) in the motif of β1 integrin displayed little developmental or ...
Josh Haram Bumm, Daniel Dogeon Lee, Zhongqiang Qiu, Angela Haeun Choi, Meghana Kolluri, Michael J. Olsen, Lianzijun Wang, Myeongwoo Lee   +7 more
wiley   +1 more source

Highlights of the 4th Drug Hypersensitivity Meeting--Rome, April 22-25, 2010

, 2011
Drug hypersensitivity is a difficult problem, but recent advances in the genetics and understanding of the immune mechanisms of various drug hypersensitivity reactions have enabled the field to make significant progress.
Romano, Antonino
core  

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort

Epilepsia Open, EarlyView.
Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman, Andreas Alexopoulos, Juan Bulacio, Dileep Nair, Vineet Punia   +4 more
wiley   +1 more source